Add like
Add dislike
Add to saved papers

MiR-182-5p: a novel biomarker in the treatment of depression in CSDS-induced mice.

BACKGROUND: Depression is a neuropsychiatric disease with high disability rate and mainly caused by the chronic stresses or genetic factors. There is increasing evidences that miRNAs play a critical role in the pathogenesis of depression. However, the underlying molecular mechanism for the pathophysiology of depression of miRNA remains entirely unclear so far.

METHODS: We first established a Chronic Social Defeat Stress (CSDS) mice model of depression, and depression-like behaviors of mice were evaluated by a series of behavioral tests. Next, we detected several abundantly expressive miRNAs that had been suggested to be involved in depression in previous reports and found miR-182-5p was selected as a candidate for analysis in the hippocampus, then western blotting and immunofluorescence were used together to examine whether AAV-siR-182-5p treatment alleviated chronic stress-induced decrease in hippocampal Akt/GSK3β/CREB signaling pathway and increase in neurogenesis impairment and neuroinflammation. Furthermore, cAMP-response element binding protein (CREB) inhibitor was adopted to examine if blockade of Akt/GSK3β/CREB signaling pathway abolished the antidepressant actions of AAV-siR-182-5p in mice.

RESULTS: Knock-down of miR-182-5p alleviated depression-like behaviors and impaired neurogenesis of CSDS-induced mice. Intriguingly, the usage of agomiR-182-5p, produced significant increases in immobility times and aggravated neuronal neurogenesis damage of mice. More importantly, it suggested that the 666-15 blocked the reversal effects of AAV-siR-182-5p on the CSDS-induced depressive-like behaviors in the behavioral testing and the neuronal neurogenesis within hippocampus of mice.

CONCLUSIONS: These findings indicated that hippocampal miR-182-5p/Akt/GSK3β/CREB signaling pathway participated in the pathogenesis of depression, itmight be given more opportunities for new drug developments based on the miRNA target in the clinic.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app